GRAIL (GRAL) Revenue & Revenue Breakdown
GRAIL Revenue Highlights
Latest Revenue (Y)
$93.11M
Latest Revenue (Q)
$35.54M
Main Geography (Y)
Americas
GRAIL Revenue by Period
GRAIL Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $93.11M | 67.61% |
| 2022-12-31 | $55.55M | 280.17% |
| 2021-12-31 | $14.61M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
GRAIL generated $93.11M in revenue during NA 2023, up 67.61% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
GRAIL Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $35.54M | 11.64% |
| 2025-03-31 | $31.84M | -16.77% |
| 2024-12-31 | $38.25M | 33.51% |
| 2024-09-30 | $28.65M | -10.38% |
| 2024-06-30 | $31.97M | 19.64% |
| 2024-03-31 | $26.72M | -11.89% |
| 2023-12-31 | $30.33M | 46.35% |
| 2023-09-30 | $20.72M | -7.55% |
| 2023-06-30 | $22.41M | 14.11% |
| 2023-04-02 | $19.64M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2019-09-30 | - | - |
GRAIL generated $35.54M in revenue during Q2 2025, up 11.64% compared to the previous quarter, and up 133.02% compared to the same period a year ago.
GRAIL Revenue Breakdown
GRAIL Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 |
|---|---|
| Americas | $108.54M |
| Non-US | $14.69M |
Latest
GRAIL's latest annual revenue breakdown by geography, as of Dec 24: Americas (88.08%), and Non-US (11.92%).
Quarterly Revenue by Country
| Country | Jun 25 | Mar 25 |
|---|---|---|
| Non-US | $1.17M | $2.45M |
| UNITED STATES | $34.21M | - |
| Americas | - | $28.70M |
Latest
GRAIL's latest quarterly revenue breakdown by geography, as of Jun 25: UNITED STATES (96.71%), and Non-US (3.29%).
GRAIL Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OGN | Organon | $6.40B | $1.59M |
| XRAY | DENTSPLY SIRONA | $3.79B | $936.00M |
| CON | Concentra Group Parent | $1.90B | $500.75M |
| HAE | Haemonetics | $1.36B | $321.39M |
| GRAL | GRAIL | $93.11M | $35.54M |
| RXRX | Recursion Pharmaceuticals | $58.84M | $19.22M |
| IBRX | ImmunityBio | $14.74M | $26.43M |
| IDYA | IDEAYA Biosciences | $7.00M | - |
| NTLA | Intellia Therapeutics | - | $16.63M |
| BEAM | Beam Therapeutics | - | - |
| DNLI | Denali Therapeutics | - | - |